Omada Health (OMDA) Evercore ISI 8th Annual HealthCONx Conference summary
Event summary combining transcript, slides, and related documents.
Evercore ISI 8th Annual HealthCONx Conference summary
13 Dec, 2025Business model and service overview
Focuses on persistent, longitudinal care for chronic diseases, offering between-visit care to improve outcomes and reduce costs.
Charges a monthly membership fee to employers and health plans, aligning incentives with clients.
Offers a suite of services covering prediabetes, obesity, diabetes, hypertension, and MSK, with the ability to add new care tracks.
GLP-1 prescribing track and operational impact
Launched a GLP-1 prescribing track to support weight loss and medication optimization, aiming to improve outcomes and cost efficiency.
Enables employers to manage medication diversity and costs through clinically responsible optimization.
Prescribing capability is an add-on, increasing client fees and designed to be accretive to revenue and margins.
Prescription costs are not included in revenue; only branded medications are prescribed.
Growth, investment, and AI strategy
2026 is positioned as an investment year to support new capabilities and AI development, balancing growth and profitability.
Long-term target is 20%+ operating margins, with a focus on leveraging business strengths and market position.
AI investments, such as OmadaSpark and Meal Map, drive engagement, retention, and operational efficiency.
AI is used to enhance both member experience and care team efficiency, supporting revenue and margin growth.
Latest events from Omada Health
- Record revenue and membership growth, first GAAP profitability, and expanded clinical offerings.OMDA
Q4 20259 Mar 2026 - 52% revenue growth, 886,000 members, and new GLP-1 prescribing drive Omada's momentum.OMDA
44th Annual J.P. Morgan Healthcare Conference14 Jan 2026 - IPO seeks $133M+ to fund growth; strong revenue, large market, but not yet profitable.OMDA
Registration Filing29 Nov 2025 - 38% revenue growth in 2024, strong retention, but still unprofitable; IPO to fund expansion.OMDA
Registration Filing29 Nov 2025 - Q2 2025 revenue rose 49% to $61.4M, margin expanded, and net loss narrowed to $5.3M.OMDA
Q2 202523 Nov 2025 - Q3 2025 delivered record revenue and member growth, positive adjusted EBITDA, and raised guidance.OMDA
Q3 202513 Nov 2025 - Strong growth, AI innovation, and GLP-1 demand drive multi-condition care platform expansion.OMDA
Morgan Stanley 23rd Annual Global Healthcare Conference12 Sep 2025